RVMD NASDAQ
Revolution Medicines, Inc.
1W: -5.3%
1M: -7.7%
3M: +2.9%
YTD: +135.7%
1Y: +241.8%
3Y: +565.8%
5Y: +577.7%
$186.22
+2.32 (+1.26%)
Weekly Expected Move ±7.2%
$160
$174
$187
$201
$214
Credit Risk of going bust: lower than 73% of companies Debt: 1.6% of company value Bonds: $112.0M held by 36 funds → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.29 (down 99.8%), Revolution Medicines, Inc. would be worth roughly what it owes.
Total debt $641.9M against a stock market value of $39.91B.
Distance to default 8.08 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $243.7M (short-term plus half of long-term), stock volatility 61.7%; Altman Z'' 1.52. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $0.29 (down 99.8%), Revolution Medicines, Inc. would be worth roughly what it owes.
Total debt $641.9M against a stock market value of $39.91B.
Distance to default 8.08 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $243.7M (short-term plus half of long-term), stock volatility 61.7%; Altman Z'' 1.52. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
#8
of 1060
Biotechnology
Technical Signal Map
16 Bullish
1 Neutral
13 Bearish
RVMD
$40B
Revolution Medicines, Inc.
BEARISH
-84
LZAGY
$54B
Lonza Group AG
BULLISH
+100
ASND
$15B
Ascendis Pharma A/S
BULLISH
+100
HALO
$14B
Halozyme Therapeutics, Inc.
BULLISH
+100
REGN
$83B
Regeneron Pharmaceuticals, Inc.
BULLISH
+91
EXEL
$16B
Exelixis, Inc.
BULLISH
+91
UTHR
$25B
United Therapeutics Corporation
BULLISH
+84
GNMSF
$28B
Genmab A/S
BULLISH
+75
NBIX
$15B
Neurocrine Biosciences, Inc.
BULLISH
+68
CSLLY
$134B
CSL Limited
BULLISH
+66
TECH
$11B
Bio-Techne Corporation
BULLISH
+58
MRNA
$80B
Moderna, Inc.
BULLISH
+56
ROIV
$26B
Roivant Sciences Ltd.
BULLISH
+50
BBIO
$13B
BridgeBio Pharma, Inc.
BULLISH
+43
ONC
$40B
BeOne Medicines AG
BULLISH
+42
VRTX
$133B
Vertex Pharmaceuticals Incorporated
BULLISH
+34
UCBJY
$58B
UCB S.A.
LEAN BULL
+28
AAVXF
$12B
Abivax S.A.
NEUTRAL
+2
ARGX
$55B
argenx SE
LEAN BEAR
-18
INCY
$23B
Incyte Corporation
LEAN BEAR
-23
WXIBF
$26B
WuXi Biologics (Cayman) Inc.
BEARISH
-35
IVBXF
$20B
Innovent Biologics, Inc.
BEARISH
-59
RVMDW
$40B
Revolution Medicines, Inc. Warrant
BEARISH
-66
ALNY
$30B
Alnylam Pharmaceuticals, Inc.
BEARISH
-66
BMRN
$11B
BioMarin Pharmaceutical Inc.
BEARISH
-69
BNTX
$22B
BioNTech SE
BEARISH
-84
JAZZ
$14B
Jazz Pharmaceuticals plc
BEARISH
-87
MDGL
$10B
Madrigal Pharmaceuticals, Inc.
BEARISH
-87
INSM
$20B
Insmed Incorporated
BEARISH
-91
SMMT
$12B
Summit Therapeutics Inc.
BEARISH
-100
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines, Inc. | $40B | -21.0 | -79.1 | 186.4 | — | — | 1 | BEARISH | 241.8 |
| LZAGY Lonza Group AG | $54B | -412.9 | 13.5 | 10.5 | 17.5 | -9.7 | 8 | BULLISH | 4.3 |
| ASND Ascendis Pharma A/S | $15B | 18.3 | 121.1 | 76.2 | 61.0 | 114.8 | 7 | BULLISH | 21.7 |
| HALO Halozyme Therapeutics, Inc. | $14B | 36.5 | 173.7 | 32.5 | 47.8 | 41.2 | 5 | BULLISH | 94.3 |
| REGN Regeneron Pharmaceuticals, Inc. | $83B | 19.5 | 14.0 | 12.9 | 30.2 | 9.3 | 7 | BULLISH | 41.4 |
| EXEL Exelixis, Inc. | $16B | 19.9 | 44.4 | 69.0 | 33.7 | 9.2 | 8 | BULLISH | 68.8 |
| UTHR United Therapeutics Corporation | $25B | 19.6 | 19.3 | 31.3 | 42.5 | 2.5 | 6 | BULLISH | 41.2 |
| GNMSF Genmab A/S | $28B | 34.9 | 3.9 | 11.9 | 26.2 | -82.1 | 4 | BULLISH | 47.7 |
| NBIX Neurocrine Biosciences, Inc. | $15B | 20.7 | 22.1 | 16.0 | 15.1 | 34.4 | 6 | BULLISH | 1.4 |
| CSLLY CSL Limited | $134B | -26.4 | -15.2 | 13.1 | -40.2 | 1.7 | 4 | BULLISH | 1.4 |
| TECH Bio-Techne Corporation | $11B | 62.1 | 9.0 | 8.9 | 17.0 | -0.4 | 7 | BULLISH | 10.3 |
| MRNA Moderna, Inc. | $80B | -26.1 | -39.0 | -90.1 | -539.3 | -27.2 | 2 | BULLISH | 724.0 |
| ROIV Roivant Sciences Ltd. | $26B | -96.2 | -6.2 | -217.5 | -13164.4 | -67.6 | 1 | BULLISH | 100.5 |
| BBIO BridgeBio Pharma, Inc. | $13B | -19.4 | 32.4 | 57.9 | -62.5 | 202.4 | 4 | BULLISH | 27.9 |
| ONC BeOne Medicines AG | $40B | 25.2 | 14.7 | 57.2 | 13.9 | 34.3 | 8 | BULLISH | 17.9 |
| VRTX Vertex Pharmaceuticals Incorporated | $133B | 30.1 | 23.5 | 28.3 | 33.0 | 10.6 | 6 | BULLISH | 23.6 |
| UCBJY UCB S.A. | $58B | 23.3 | 20.7 | 16.4 | 26.0 | 25.3 | 6 | LEAN BULL | 5.8 |
| AAVXF Abivax S.A. | $12B | -17.0 | -221.8 | 440.6 | — | -133.5 | 4 | NEUTRAL | 57.0 |
| ARGX argenx SE | $55B | 41.0 | 26.0 | 50.1 | 29.8 | 162.5 | 7 | LEAN BEAR | 8.0 |
| INCY Incyte Corporation | $23B | 14.3 | 30.7 | 82.1 | 35.0 | 26.9 | 8 | LEAN BEAR | 27.7 |
| WXIBF WuXi Biologics (Cayman) Inc. | $26B | 31.4 | 10.6 | 16.0 | 20.7 | 16.0 | 9 | BEARISH | 20.2 |
| IVBXF Innovent Biologics, Inc. | $20B | 96.9 | 6.9 | 67.2 | 14.5 | 35.4 | 6 | BEARISH | -11.4 |
| RVMDW Revolution Medicines, Inc. Warrant | $40B | -21.0 | -79.1 | 186.4 | — | — | 1 | BEARISH | 2251.5 |
| ALNY Alnylam Pharmaceuticals, Inc. | $30B | 37.2 | 100.7 | -152.8 | 12.7 | 95.1 | 6 | BEARISH | -51.1 |
| BMRN BioMarin Pharmaceutical Inc. | $11B | 145.7 | 1.2 | 1.4 | 4.5 | 11.2 | 4 | BEARISH | 1.6 |
| BNTX BioNTech SE | $22B | -11.5 | -9.3 | -18.0 | -777.3 | -8.2 | 2 | BEARISH | -17.6 |
| JAZZ Jazz Pharmaceuticals plc | $14B | 13.6 | 22.1 | 26.4 | 16.0 | 12.6 | 8 | BEARISH | 49.3 |
| MDGL Madrigal Pharmaceuticals, Inc. | $10B | -34.2 | -53.3 | -778.9 | -15.9 | 149.0 | 2 | BEARISH | 4.5 |
| INSM Insmed Incorporated | $20B | -23.1 | -87.2 | -364.8 | -3.1 | 185.8 | 5 | BEARISH | -40.5 |
| SMMT Summit Therapeutics Inc. | $12B | -13.7 | -192.5 | 1714.4 | — | — | 3 | BEARISH | -20.5 |
| RVMD Revolution Medicines, Inc. | $40B | -21.0 | -79.1 | 186.4 | — | — | 1 | BEARISH | 241.8 |
| ILMN Illumina, Inc. | $41B | 51.7 | 32.4 | 18.2 | 17.9 | 4.9 | 7 | BULLISH | 179.2 |
| SDZNY Sandoz Group AG | $42B | 66.5 | 7.2 | 10.1 | 1.9 | 29.1 | 6 | BULLISH | 59.1 |
| MTD Mettler-Toledo International Inc. | $33B | 37.8 | -736.4 | 46.7 | 22.7 | 6.9 | 8 | BULLISH | 17.5 |
| ORINY Orion Oyj | $30B | 23.0 | 53.6 | 46.3 | 26.9 | 22.6 | 7 | BULLISH | 44.0 |
| GEHC GE HealthCare Technologies Inc. | $32B | 20.4 | 15.4 | 10.6 | 10.8 | 1.4 | 5 | BULLISH | -9.0 |
| IDXX IDEXX Laboratories, Inc. | $44B | 39.4 | 74.2 | 46.5 | 27.8 | 12.8 | 9 | BULLISH | -12.4 |
| ZTS Zoetis Inc. | $33B | 12.9 | 64.4 | 26.3 | 28.0 | 1.4 | 6 | BULLISH | -46.2 |
| BIIB Biogen Inc. | $37B | 44.5 | 4.6 | 4.8 | 3.6 | -0.5 | 3 | BULLISH | 68.6 |
| WAT Waters Corporation | $45B | 116.6 | 1.9 | 1.5 | -8.3 | 52.5 | 5 | BULLISH | 30.3 |
| OTSKY Otsuka Holdings Co., Ltd. | $42B | 16.0 | 13.8 | 12.2 | 16.7 | 10.9 | 8 | BULLISH | 44.2 |
| IQV IQVIA Holdings Inc. | $46B | 32.6 | 21.7 | 33.3 | 7.9 | 8.8 | 9 | BULLISH | 23.1 |
| A Agilent Technologies, Inc. | $49B | 34.9 | 21.0 | 14.9 | 19.3 | 8.6 | 7 | BULLISH | 19.9 |
| CNC Centene Corp. | $35B | 23.2 | 6.8 | 6.4 | -0.1 | 4.8 | 7 | BULLISH | 101.6 |
| HLN Haleon plc | $45B | 20.7 | 10.1 | 8.4 | 13.6 | 1.3 | 8 | BULLISH | 8.9 |
| ALC Alcon Inc. | $34B | 53.4 | 2.9 | 3.6 | 0.0 | 7.8 | 6 | BULLISH | -8.8 |
| TEVA Teva Pharmaceutical Industries Limited | $46B | 64.1 | 9.7 | 9.3 | -13.9 | 4.1 | 7 | BULLISH | 113.2 |
| ALPMF Astellas Pharma Inc. | $30B | 12.4 | 21.4 | 16.9 | 22.1 | 17.3 | 7 | LEAN BULL | 60.4 |
| BAYRY Bayer AG | $48B | -26.2 | -5.5 | 6.4 | 2.0 | -1.5 | 4 | LEAN BEAR | 59.6 |
| DSNKY Daiichi Sankyo Company, Limited | $33B | 19.6 | 15.1 | 12.5 | 11.9 | 17.4 | 5 | LEAN BEAR | -37.5 |
| RSMDF ResMed Inc. | $36B | 24.0 | 24.3 | 25.3 | 26.2 | 9.9 | 7 | BEARISH | -15.5 |
| RVMD Revolution Medicines, Inc. | $40B | -21.0 | -79.1 | 186.4 | — | — | 1 | BEARISH | 241.8 |
| ABBV AbbVie Inc. | $505B | 80.7 | -206.4 | 23.5 | 21.3 | 10.4 | 7 | BULLISH | 25.6 |
| TKPHF Takeda Pharmaceutical Company Limited | $66B | 56.1 | 2.5 | 2.8 | 9.3 | 3.3 | 6 | BULLISH | 41.6 |
| LZAGY Lonza Group AG | $54B | -412.9 | 13.5 | 10.5 | 17.5 | -9.7 | 8 | BULLISH | 4.3 |
| RPRX Royalty Pharma plc | $28B | 27.1 | 12.4 | 10.6 | 2.7 | 10.0 | 6 | BULLISH | 76.2 |
| WST West Pharmaceutical Services, Inc. | $28B | 50.6 | 19.1 | 19.0 | 17.7 | 12.4 | 9 | BULLISH | 34.0 |
| LH Labcorp Holdings Inc. | $27B | 27.2 | 11.7 | 8.6 | 8.0 | 6.4 | 8 | BULLISH | 19.8 |
| MEDP Medpace Holdings, Inc. | $19B | 36.7 | 117.9 | 1953.7 | 19.2 | 20.4 | 9 | BULLISH | 11.3 |
| CRL Charles River Laboratories International, Inc. | $17B | -74.1 | -7.7 | 6.9 | -0.1 | -0.7 | 4 | BULLISH | 82.2 |
| ASND Ascendis Pharma A/S | $15B | 18.3 | 121.1 | 76.2 | 61.0 | 114.8 | 7 | BULLISH | 21.7 |
| HALO Halozyme Therapeutics, Inc. | $14B | 36.5 | 173.7 | 32.5 | 47.8 | 41.2 | 5 | BULLISH | 94.3 |
| QGEN Qiagen N.V. | $10B | 25.7 | 11.9 | 11.2 | 19.3 | 3.0 | 8 | BULLISH | 1.7 |
| JNJ Johnson & Johnson | $636B | 40.7 | 20.0 | 21.3 | 0.8 | 7.8 | 6 | BULLISH | 42.0 |
| TMO Thermo Fisher Scientific Inc. | $249B | 36.5 | 13.4 | 8.6 | 14.2 | 8.3 | 8 | BULLISH | 21.2 |
| DHR Danaher Corporation | $162B | 37.9 | 8.3 | 6.3 | 18.8 | 5.5 | 7 | BULLISH | 4.8 |
| MDT Medtronic Plc | $122B | 23.0 | 10.7 | 7.8 | 15.1 | 9.8 | 9 | BULLISH | 3.6 |
| REGN Regeneron Pharmaceuticals, Inc. | $83B | 19.5 | 14.0 | 12.9 | 30.2 | 9.3 | 7 | BULLISH | 41.4 |
| CI Cigna Corporation | $81B | 12.3 | 15.5 | 11.8 | 2.3 | 7.7 | 8 | BULLISH | -0.6 |
| EW Edwards Lifesciences Corporation | $51B | 52.2 | 9.5 | 17.9 | 13.9 | 14.6 | 6 | BULLISH | 19.3 |
| SDZNY Sandoz Group AG | $42B | 66.5 | 7.2 | 10.1 | 1.9 | 29.1 | 6 | BULLISH | 59.1 |
| ILMN Illumina, Inc. | $41B | 51.7 | 32.4 | 18.2 | 17.9 | 4.9 | 7 | BULLISH | 179.2 |
| MTD Mettler-Toledo International Inc. | $33B | 37.8 | -736.4 | 46.7 | 22.7 | 6.9 | 8 | BULLISH | 17.5 |
| ORINY Orion Oyj | $30B | 23.0 | 53.6 | 46.3 | 26.9 | 22.6 | 7 | BULLISH | 44.0 |
| EXEL Exelixis, Inc. | $16B | 19.9 | 44.4 | 69.0 | 33.7 | 9.2 | 8 | BULLISH | 68.8 |
| PMCUF Pro Medicus Limited | $13B | 78.4 | 75.0 | 68.1 | 68.7 | 22.8 | 7 | BULLISH | -33.0 |
| AVTR Avantor, Inc. | $12B | -20.4 | -9.7 | -2.5 | 2.3 | -1.6 | 6 | BULLISH | 11.1 |
| GKOS Glaukos Corporation | $11B | -55.7 | -26.0 | -12.7 | -9.9 | 41.5 | 3 | BULLISH | 142.7 |
| GEHC GE HealthCare Technologies Inc. | $32B | 20.4 | 15.4 | 10.6 | 10.8 | 1.4 | 5 | BULLISH | -9.0 |
| ABT Abbott Laboratories | $179B | 38.2 | 10.7 | 7.3 | 7.4 | 8.1 | 5 | BULLISH | -18.7 |
| SNY Sanofi | $100B | 23.0 | 5.7 | 6.4 | 2.8 | 13.4 | 6 | BULLISH | -18.9 |
| UTHR United Therapeutics Corporation | $25B | 19.6 | 19.3 | 31.3 | 42.5 | 2.5 | 6 | BULLISH | 41.2 |
| GH Guardant Health, Inc. | $23B | -51.0 | 171.6 | -88.3 | -35.9 | 42.7 | 6 | BULLISH | 146.8 |
| RDY Dr. Reddy's Laboratories Limited | $11B | 39.0 | 7.5 | 6.0 | 10.7 | -3.1 | 4 | BULLISH | -5.7 |
| PODD Insulet Corp. | $10B | 28.0 | 26.0 | 21.3 | 11.8 | 29.4 | 9 | BULLISH | -53.3 |
| PFE Pfizer Inc. | $171B | 39.4 | 5.0 | 11.3 | -1.6 | -0.2 | 7 | BULLISH | 22.5 |
| MCK McKesson Corporation | $117B | 25.8 | -148.0 | 237.7 | 0.6 | 8.8 | 8 | BULLISH | 20.7 |
| WILYY Demant A/S | $12B | 46.8 | 15.9 | 10.9 | 9.1 | 10.6 | 5 | BULLISH | 47.3 |
| NTRA Natera, Inc. | $58B | -302.1 | -12.5 | -23.6 | -8.9 | 37.8 | 6 | BULLISH | 113.4 |
| IDXX IDEXX Laboratories, Inc. | $44B | 39.4 | 74.2 | 46.5 | 27.8 | 12.8 | 9 | BULLISH | -12.4 |
| ZTS Zoetis Inc. | $33B | 12.9 | 64.4 | 26.3 | 28.0 | 1.4 | 6 | BULLISH | -46.2 |
| CLPBY Coloplast A/S | $17B | 38.9 | 18.5 | 70.9 | 19.9 | -2.9 | 5 | BULLISH | -23.4 |
| SNN Smith & Nephew plc | $13B | 19.7 | 11.8 | 9.9 | 9.8 | 5.3 | 7 | BULLISH | -15.5 |
| PEN Penumbra, Inc. | $13B | 79.2 | 11.4 | 13.6 | 8.9 | 17.6 | 6 | BULLISH | 28.1 |
| COO The Cooper Companies, Inc. | $12B | 20.4 | 6.8 | 6.3 | 40.6 | 4.7 | 6 | BULLISH | -18.5 |
| RHHBF Roche Holding AG | $393B | 26.0 | 40.2 | 24.6 | 22.6 | 27.8 | 6 | BULLISH | 30.5 |
| NVS Novartis AG | $287B | 23.6 | 30.6 | 16.8 | 22.7 | 0.8 | 5 | BULLISH | 20.3 |
| GILD Gilead Sciences, Inc. | $193B | -61.2 | -20.6 | -3.4 | -134.5 | 5.5 | 5 | BULLISH | 32.4 |
| ISRG Intuitive Surgical, Inc. | $160B | 53.3 | 18.0 | 22.6 | 17.1 | 20.5 | 7 | BULLISH | -18.4 |
| CVS CVS Health Corp. | $120B | 23.8 | 6.2 | 4.9 | 2.8 | 7.4 | 8 | BULLISH | 11.2 |
| SYK Stryker Corporation | $118B | 31.0 | 16.5 | 11.6 | 19.4 | 8.5 | 9 | BULLISH | -21.0 |
| SOAGY Sartorius AG ADR | $92B | 92.0 | 7.7 | 6.6 | 7.1 | 4.3 | 7 | BULLISH | 16.0 |
| WAT Waters Corporation | $45B | 116.6 | 1.9 | 1.5 | -8.3 | 52.5 | 5 | BULLISH | 30.3 |
| BIIB Biogen Inc. | $37B | 44.5 | 4.6 | 4.8 | 3.6 | -0.5 | 3 | BULLISH | 68.6 |
| GNMSF Genmab A/S | $28B | 34.9 | 3.9 | 11.9 | 26.2 | -82.1 | 4 | BULLISH | 47.7 |
| VTRS Viatris Inc. | $21B | -52.0 | -2.8 | -0.3 | -3.2 | 4.4 | 7 | BULLISH | 83.0 |
| ALGN Align Technology, Inc. | $11B | 26.4 | 10.2 | 12.3 | 10.3 | 4.4 | 7 | BULLISH | 12.4 |
| CHGCF Chugai Pharmaceutical Co., Ltd. | $74B | 23.3 | 23.7 | 45.1 | 34.1 | 12.6 | 6 | BULLISH | -0.7 |
| NBIX Neurocrine Biosciences, Inc. | $15B | 20.7 | 22.1 | 16.0 | 15.1 | 34.4 | 6 | BULLISH | 1.4 |
| LLY Eli Lilly and Company | $1.2T | 42.9 | 102.4 | 39.2 | 30.9 | 49.6 | 9 | BULLISH | 55.5 |
| AMGN Amgen Inc. | $237B | 27.6 | 91.5 | 19.5 | 23.6 | 9.2 | 8 | BULLISH | 57.8 |
| CSLLY CSL Limited | $134B | -26.4 | -15.2 | 13.1 | -40.2 | 1.7 | 4 | BULLISH | 1.4 |
| CAH Cardinal Health, Inc. | $58B | 33.9 | -60.5 | 92.8 | 0.6 | 14.2 | 8 | BULLISH | 53.7 |
| BDX Becton, Dickinson and Company | $54B | 58.7 | 3.8 | 4.1 | 7.6 | -2.6 | 6 | BULLISH | 5.5 |
| A Agilent Technologies, Inc. | $49B | 34.9 | 21.0 | 14.9 | 19.3 | 8.6 | 7 | BULLISH | 19.9 |
| IQV IQVIA Holdings Inc. | $46B | 32.6 | 21.7 | 33.3 | 7.9 | 8.8 | 9 | BULLISH | 23.1 |
| OTSKY Otsuka Holdings Co., Ltd. | $42B | 16.0 | 13.8 | 12.2 | 16.7 | 10.9 | 8 | BULLISH | 44.2 |
| TRUMY Terumo Corporation | $22B | 21.5 | 11.0 | 9.6 | 22.6 | 15.6 | 5 | BULLISH | -8.6 |
| SONVF Sonova Holding AG | $20B | 38.9 | 20.4 | 17.2 | 19.7 | -7.1 | 6 | BULLISH | 22.9 |
| ZBH Zimmer Biomet Holdings, Inc. | $19B | 23.3 | 6.4 | 5.9 | 9.1 | 8.6 | 6 | BULLISH | -6.8 |
| ICLR ICON Public Limited Company | $14B | 42.6 | 3.5 | 5.5 | 3.5 | 2.0 | 6 | BULLISH | 2.7 |
| FSNUY Fresenius SE & Co. KGaA | $117B | 16.8 | 8.1 | 5.6 | 6.4 | 5.9 | 7 | BULLISH | -20.4 |
| GSK GSK plc | $102B | 16.0 | 25.5 | 18.8 | 5.2 | 5.0 | 7 | BULLISH | 18.9 |
| SEMHF Siemens Healthineers AG | $53B | 21.1 | 12.1 | 8.4 | 11.6 | 10.0 | 9 | BULLISH | -17.9 |
| DGX Quest Diagnostics Incorporated | $27B | 23.8 | 15.2 | 10.2 | 10.1 | 9.1 | 8 | BULLISH | 33.1 |
| SAUHY Straumann Holding AG | $19B | 41.9 | 17.3 | 21.7 | 18.1 | 3.0 | 6 | BULLISH | 4.9 |
| CNC Centene Corp. | $35B | 23.2 | 6.8 | 6.4 | -0.1 | 4.8 | 7 | BULLISH | 101.6 |
| RVTY Revvity, Inc. | $18B | 77.1 | 3.2 | 3.5 | 7.1 | 5.5 | 6 | BULLISH | 63.7 |
| BAX Baxter International Inc. | $13B | -12.2 | -15.7 | -1.6 | 4.3 | 5.4 | 3 | BULLISH | 8.4 |
| TECH Bio-Techne Corporation | $11B | 62.1 | 9.0 | 8.9 | 17.0 | -0.4 | 7 | BULLISH | 10.3 |
| MRNA Moderna, Inc. | $80B | -26.1 | -39.0 | -90.1 | -539.3 | -27.2 | 2 | BULLISH | 724.0 |
| HOCPY HOYA Corporation | $56B | 33.3 | 27.3 | 46.1 | 25.7 | 14.2 | 6 | BULLISH | 12.2 |
| HLN Haleon plc | $45B | 20.7 | 10.1 | 8.4 | 13.6 | 1.3 | 8 | BULLISH | 8.9 |
| ALC Alcon Inc. | $34B | 53.4 | 2.9 | 3.6 | 0.0 | 7.8 | 6 | BULLISH | -8.8 |
| PHG Koninklijke Philips N.V. | $26B | 20.3 | 10.2 | 7.6 | 8.8 | -1.1 | 6 | BULLISH | -8.4 |
| STE STERIS plc | $23B | 27.9 | 11.4 | 9.7 | 13.4 | 8.4 | 8 | BULLISH | -4.9 |
| SRTOY Sartorius Stedim Biotech S.A. | $228B | 66.4 | 7.4 | 6.2 | 12.5 | 4.4 | 8 | BULLISH | -0.5 |
| ESLOF EssilorLuxottica S.A. | $94B | 33.7 | 6.5 | 5.2 | 10.6 | 7.4 | 6 | BULLISH | -44.5 |
| BSX Boston Scientific Corporation | $66B | 18.2 | 15.5 | 11.6 | 16.7 | 13.5 | 8 | BULLISH | -55.4 |
| ROIV Roivant Sciences Ltd. | $26B | -96.2 | -6.2 | -217.5 | -13164.4 | -67.6 | 1 | BULLISH | 100.5 |
| BMXXY bioMérieux S.A. | $12B | 22.8 | 11.2 | 8.9 | 11.5 | -3.5 | 7 | BULLISH | -28.0 |
| GMED Globus Medical, Inc. | $11B | 20.4 | 11.8 | 12.3 | 19.2 | 19.7 | 8 | BULLISH | 29.8 |
| ELV Elevance Health Inc. | $95B | 18.0 | 11.6 | 16.2 | 2.7 | 3.6 | 7 | BULLISH | 23.7 |
| TEVA Teva Pharmaceutical Industries Limited | $46B | 64.1 | 9.7 | 9.3 | -13.9 | 4.1 | 7 | BULLISH | 113.2 |
| BBIO BridgeBio Pharma, Inc. | $13B | -19.4 | 32.4 | 57.9 | -62.5 | 202.4 | 4 | BULLISH | 27.9 |
| ONC BeOne Medicines AG | $40B | 25.2 | 14.7 | 57.2 | 13.9 | 34.3 | 8 | BULLISH | 17.9 |
| UNH UnitedHealth Group Incorporated | $375B | 23.4 | 15.9 | 13.5 | 3.6 | 3.3 | 7 | BULLISH | 14.0 |
| FSPKF Fisher & Paykel Healthcare Corporation Limited | $16B | 59.5 | 23.3 | 27.3 | 20.6 | 5.0 | 6 | BULLISH | 34.9 |
| RCDTF Recordati Industria Chimica e Farmaceutica S.p.A. | $12B | 21.7 | 24.9 | 15.4 | 16.7 | 9.2 | 7 | BULLISH | -9.2 |
| VRTX Vertex Pharmaceuticals Incorporated | $133B | 30.1 | 23.5 | 28.3 | 33.0 | 10.6 | 6 | BULLISH | 23.6 |
| SGIOY Shionogi & Co., Ltd. | $16B | 9.8 | 13.6 | 9.9 | 50.6 | 10.3 | 5 | BULLISH | 20.6 |
| ERFSF Eurofins Scientific SE | $17B | 28.5 | 12.8 | 4.6 | 8.2 | 3.3 | 6 | BULLISH | 25.6 |
| HUM Humana Inc. | $51B | 39.0 | 6.8 | 17.2 | 1.7 | 18.3 | 4 | BULLISH | 42.7 |
| UCBJY UCB S.A. | $58B | 23.3 | 20.7 | 16.4 | 26.0 | 25.3 | 6 | LEAN BULL | 5.8 |
| BIOVF Swedish Orphan Biovitrum AB | $16B | 116.9 | 3.4 | 17.2 | 14.0 | 13.3 | 4 | LEAN BULL | 37.3 |
| AZN AstraZeneca PLC | $266B | 25.4 | 22.0 | 15.0 | 16.3 | 8.6 | 9 | LEAN BULL | 4.5 |
| IPSEY Ipsen S.A. | $58B | 24.6 | 11.5 | 16.3 | 18.2 | 8.0 | 6 | LEAN BULL | 22.7 |
| BMY Bristol-Myers Squibb Company | $126B | 13.6 | 46.7 | 17.8 | 25.6 | 3.1 | 8 | LEAN BULL | 46.8 |
| MKGAF Merck KGaA | $70B | 26.5 | 8.1 | 8.1 | 9.0 | -0.4 | 7 | LEAN BULL | 19.4 |
| ALPMF Astellas Pharma Inc. | $30B | 12.4 | 21.4 | 16.9 | 22.1 | 17.3 | 7 | LEAN BULL | 60.4 |
| JDHIY JD Health International Inc. | $16B | 16.4 | 10.3 | 31.0 | 8.4 | 19.6 | 6 | LEAN BULL | -43.9 |
| TEM Tempus AI, Inc. | $12B | -50.5 | -67.4 | -19.8 | 1.5 | 50.4 | 4 | LEAN BULL | -19.1 |
| FMS Fresenius Medical Care AG & Co. KGaA | $12B | 12.2 | 7.3 | 6.7 | 4.5 | -0.5 | 7 | NEUTRAL | -17.4 |
| COR Cencora, Inc. | $63B | 24.1 | 104.3 | 26.5 | 0.9 | 5.1 | 7 | NEUTRAL | -2.0 |
| HCA HCA Healthcare, Inc. | $102B | 54.6 | -124.7 | 23.3 | 8.4 | 7.3 | 6 | NEUTRAL | 0.8 |
| AAVXF Abivax S.A. | $12B | -17.0 | -221.8 | 440.6 | — | -133.5 | 4 | NEUTRAL | 57.0 |
| CHJTF CSPC Pharmaceutical Group Limited | $14B | 10.3 | 20.7 | 36.7 | 32.8 | 88.1 | 6 | NEUTRAL | 13.3 |
| DVA DaVita Inc. | $12B | 15.6 | -149.4 | 17.9 | 7.5 | 6.4 | 8 | NEUTRAL | 40.7 |
| NONOF Novo Nordisk A/S | $172B | 9.9 | 59.8 | 35.2 | 26.7 | 5.6 | 5 | NEUTRAL | -28.1 |
| IHHHF IHH Healthcare Berhad | $15B | 30.9 | 7.3 | 6.1 | 8.1 | 7.1 | 5 | NEUTRAL | 43.7 |
| BAYRY Bayer AG | $48B | -26.2 | -5.5 | 6.4 | 2.0 | -1.5 | 4 | LEAN BEAR | 59.6 |
| SUVPF Sartorius AG | $19B | 92.0 | 7.7 | 6.7 | 7.1 | 3.6 | 7 | LEAN BEAR | -0.5 |
| ARGX argenx SE | $55B | 41.0 | 26.0 | 50.1 | 29.8 | 162.5 | 7 | LEAN BEAR | 8.0 |
| MOH Molina Healthcare, Inc. | $11B | -327.0 | -1.2 | -44.2 | 0.4 | -2.1 | 5 | LEAN BEAR | 22.1 |
| INCY Incyte Corporation | $23B | 14.3 | 30.7 | 82.1 | 35.0 | 26.9 | 8 | LEAN BEAR | 27.7 |
| DSNKY Daiichi Sankyo Company, Limited | $33B | 19.6 | 15.1 | 12.5 | 11.9 | 17.4 | 5 | LEAN BEAR | -37.5 |
| BTSG BrightSpring Health Services, Inc. Common Stock | $12B | 40.8 | 15.5 | 10.3 | 2.2 | 19.9 | 7 | LEAN BEAR | 74.0 |
| WXIBF WuXi Biologics (Cayman) Inc. | $26B | 31.4 | 10.6 | 16.0 | 20.7 | 16.0 | 9 | BEARISH | 20.2 |
| EHC Encompass Health Corporation | $12B | 19.5 | 25.5 | 16.7 | 9.6 | 9.5 | 9 | BEARISH | -3.7 |
| RSMDF ResMed Inc. | $36B | 24.0 | 24.3 | 25.3 | 26.2 | 9.9 | 7 | BEARISH | -15.5 |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | $12B | 40.8 | 15.5 | 10.3 | 2.2 | 19.9 | 7 | BEARISH | 68.8 |
| UHS Universal Health Services, Inc. | $11B | 7.4 | 21.0 | 12.5 | 7.7 | 10.0 | 8 | BEARISH | -15.7 |
| RGEN Repligen Corporation | $11B | -837.1 | -0.6 | -1.4 | -18.4 | 13.8 | 4 | BEARISH | 5.7 |
| SOLV Solventum Corporation | $15B | 10.1 | 34.0 | 18.1 | 4.2 | -0.9 | 7 | BEARISH | 16.2 |
| THC Tenet Healthcare Corporation | $22B | 10.0 | 53.3 | 19.1 | 14.7 | 5.4 | 7 | BEARISH | 24.5 |
| OCPNF Olympus Corporation | $12B | 24.4 | 10.6 | 12.7 | 7.9 | 7.8 | 5 | BEARISH | -9.8 |
| IVBXF Innovent Biologics, Inc. | $20B | 96.9 | 6.9 | 67.2 | 14.5 | 35.4 | 6 | BEARISH | -11.4 |
| ELAN Elanco Animal Health Incorporated | $11B | -55.2 | -3.0 | 3.7 | 3.9 | 12.0 | 5 | BEARISH | 2.7 |
| RVMDW Revolution Medicines, Inc. Warrant | $40B | -21.0 | -79.1 | 186.4 | — | — | 1 | BEARISH | 2251.5 |
| ALNY Alnylam Pharmaceuticals, Inc. | $30B | 37.2 | 100.7 | -152.8 | 12.7 | 95.1 | 6 | BEARISH | -51.1 |
| ENSG The Ensign Group, Inc. | $10B | 24.5 | 17.0 | 8.1 | 6.9 | 18.9 | 7 | BEARISH | -8.9 |
| MRK Merck & Co., Inc. | $358B | 112.6 | 7.0 | 6.1 | -8.0 | 4.5 | 4 | BEARISH | 63.5 |
| BMRN BioMarin Pharmaceutical Inc. | $11B | 145.7 | 1.2 | 1.4 | 4.5 | 11.2 | 4 | BEARISH | 1.6 |
| WUXAY WuXi AppTec Co., Ltd. | $68B | 15.4 | 30.2 | 35.4 | 39.1 | 25.0 | 8 | BEARISH | 66.6 |
| DXCM DexCom, Inc. | $29B | 30.3 | 38.5 | 42.9 | 19.0 | 15.5 | 9 | BEARISH | 11.7 |
| BNTX BioNTech SE | $22B | -11.5 | -9.3 | -18.0 | -777.3 | -8.2 | 2 | BEARISH | -17.6 |
| JAZZ Jazz Pharmaceuticals plc | $14B | 13.6 | 22.1 | 26.4 | 16.0 | 12.6 | 8 | BEARISH | 49.3 |
| MDGL Madrigal Pharmaceuticals, Inc. | $10B | -34.2 | -53.3 | -778.9 | -15.9 | 149.0 | 2 | BEARISH | 4.5 |
| INSM Insmed Incorporated | $20B | -23.1 | -87.2 | -364.8 | -3.1 | 185.8 | 5 | BEARISH | -40.5 |
| GIKLY Grifols, S.A. | $15B | 15.9 | 8.4 | 7.4 | 8.2 | -0.2 | 6 | BEARISH | -19.0 |
| MDLN Medline Inc. | $30B | 37.7 | 3.2 | 4.4 | 0.8 | — | 4 | BEARISH | — |
| SMMT Summit Therapeutics Inc. | $12B | -13.7 | -192.5 | 1714.4 | — | — | 3 | BEARISH | -20.5 |
| SBMFF Sino Biopharmaceutical Limited | $12B | 30.4 | 21.1 | 40.0 | 17.7 | 28.2 | 7 | BEARISH | -22.9 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
RVMD vs Benchmarks
ROIC
P/E Ratio
ROE
Piotroski F